What was the overall market valuation of the US black lung-disease market in 2024?

The overall market valuation was $333.9 Million in 2024. Read More

What is the projected market valuation for the US black lung-disease market in 2035?

The projected valuation for 2035 is $523.34 Million. Read More

What is the expected CAGR for the US black lung-disease market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 4.17%. Read More

Which companies are key players in the US black lung-disease market?

Key players include Bristol-Myers Squibb, Johnson & Johnson, Pfizer, Merck & Co, GlaxoSmithKline, AstraZeneca, Novartis, Roche, and Sanofi. Read More

What were the segment valuations for Chronic Obstructive Pulmonary Disease in 2024?

The segment valuation for Chronic Obstructive Pulmonary Disease was $100.0 Million to $150.0 Million. Read More

How much was the valuation for Pneumoconiosis in 2024?

The valuation for Pneumoconiosis ranged from $120.0 Million to $180.0 Million in 2024. Read More

What is the projected valuation for Coal Workers' Pneumoconiosis in 2035?

The projected valuation for Coal Workers' Pneumoconiosis in 2035 is expected to be between $113.9 Million and $193.34 Million. Read More

What were the segment valuations for diagnostic methods in 2024?

In 2024, the segment valuations for diagnostic methods were $100.0 Million for Chest X-Ray, $150.0 Million for CT Scan, and $83.9 Million for Pulmonary Function Test. Read More

What is the expected valuation for medication as a treatment type in 2035?

The expected valuation for medication as a treatment type in 2035 is projected to be between $133.17 Million and $205.33 Million. Read More

What were the segment valuations for end users in 2024?

The segment valuations for end users in 2024 included $133.9 Million for hospitals, $100.0 Million for diagnostic laboratories, and $100.0 Million for research institutes. Read More

US Black Lung Disease Market

ID: MRFR/Pharma/18336-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Black Lung Disease Market Research Report By Disease Type (Chronic Obstructive Pulmonary Disease, Pneumoconiosis, Coal Workers' Pneumoconiosis), By Diagnostic Method (Chest X-ray, CT Scan, Pulmonary Function Test), By Treatment Type (Medication, Pulmonary Rehabilitation, Surgical Procedures) and By End User (Hospitals, Diagnostic Laboratories, Research Institutes) - Growth & Industry Forecast 2025 To 2035

US Black Lung Disease Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Disease Type (USD Million)
  1. 4.1.1 Chronic Obstructive Pulmonary Disease
  2. 4.1.2 Pneumoconiosis
  3. 4.1.3 Coal Workers' Pneumoconiosis
2. 4.2 Pharmaceutical, BY Diagnostic Method (USD Million)
  1. 4.2.1 Chest X-Ray
  2. 4.2.2 CT Scan
  3. 4.2.3 Pulmonary Function Test
3. 4.3 Pharmaceutical, BY Treatment Type (USD Million)
  1. 4.3.1 Medication
  2. 4.3.2 Pulmonary Rehabilitation
  3. 4.3.3 Surgical Procedures
4. 4.4 Pharmaceutical, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Diagnostic Laboratories
  3. 4.4.3 Research Institutes
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol-Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Johnson & Johnson (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Merck & Co (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 GlaxoSmithKline (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Roche (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DISEASE TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSTIC METHOD
4. 6.4 US MARKET ANALYSIS BY TREATMENT TYPE
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY DISEASE TYPE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY DISEASE TYPE, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY DIAGNOSTIC METHOD, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY DIAGNOSTIC METHOD, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY TREATMENT TYPE, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Pharmaceutical Market Segmentation

Pharmaceutical By Disease Type (USD Million, 2025-2035)

Chronic Obstructive Pulmonary Disease
Pneumoconiosis
Coal Workers' Pneumoconiosis

Pharmaceutical By Diagnostic Method (USD Million, 2025-2035)

Chest X-Ray
CT Scan
Pulmonary Function Test

Pharmaceutical By Treatment Type (USD Million, 2025-2035)

Medication
Pulmonary Rehabilitation
Surgical Procedures

Pharmaceutical By End User (USD Million, 2025-2035)

Hospitals
Diagnostic Laboratories
Research Institutes

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”